Table 1.
Clinical-demographical characteristics of NSCLC dataset
| Adenocarcinoma-mRNA (complete dataset) |
Adenocarcinoma-mRNA (For survival analysis) |
Squamous Carcinoma-mRNA (complete dataset) |
Squamous Carcinoma-mRNA (For survival analysis) |
Adenocarcinoma -protein (complete dataset) |
Squamous Carcinoma-protein (complete dataset) |
|||
|---|---|---|---|---|---|---|---|---|
| Mayo Clinic dataset (DASL, N=77) |
TCGA dataset (RNA-seq V2, N=288) |
Mayo Clinic dataset (DASL, N=77) |
TCGA dataset (RNA-seq V2, N=188) |
TCGA dataset (RNA-seq V2, N=220) |
TCGA dataset (RNA-seq V2, N=169) |
Daping Hospital (IHC, N=75) |
Daping Hospital (IHC, N=75) |
|
| Age | ||||||||
| N | 77 | 269 | 77 | 188 | 212 | 169 | 74 | 75 |
| Mean (SD) | 67.8(12.9) | 65.6(9.7) | 67.8(12.9) | 64.8(10.1) | 67.5(8.4) | 67.8(8.2) | 60.9 | 64.4(8.1) |
| Gender | ||||||||
| Male | 14(18.2%) | 133(46.2%) | 14(18.2%) | 94(50.0%) | 161(73.2%) | 124(73.4%) | 41(54.7%) | 71(94.7%) |
| Female | 63(81.8%) | 155(53.8%) | 63(81.8%) | 94(50.0%) | 59(26.8%) | 45(26.6%) | 34(45.3%) | 4(5.3%) |
| Tumor stage | ||||||||
| I | 51(66.2%) | 147(51.0%) | 51(66.2%) | 95(50.5%) | 114(51.8%) | 91(53.8%) | 27(36.0%) | 27(36.0%) |
| II | 9(11.7%) | 61(21.2%) | 9(11.7%) | 39(20.7%) | 53(24.1%) | 37(21.9%) | 16(21.3%) | 28(37.3%) |
| III | 17(22.1%) | 58(20.1%) | 17(22.1%) | 41(21.8%) | 46(20.9%) | 36(21.3%) | 27(36.0%) | 18(24.0%) |
| IV | 0 (0.0%) | 16(5.6%) | 0 (0.0%) | 10(5.3%) | 4(1.8%) | 3(1.8%) | 5(6.7%) | 2(2.7%) |
| Unknown | 0(0.0%) | 6(2.1%) | 0(0.0%) | 3(1.6%) | 3(1.4%) | 2(1.2%) | 0(0.0%) | 0(0.0%) |
| Smoking | ||||||||
| Never smoker | 77(100%) | 36(12.5%) | 77(100%) | 0(0.0%) | 10(4.5%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
| Current/Ever smoker | 0(0.0%) | 240(83.3%) | 0(0.0%) | 188(100%) | 204(92.7%) | 169(100%) | 0(0.0%) | 0(0.0%) |
| Unknown | 0(0.0%) | 12(4.2%) | 0(0.0%) | 0(0.0%) | 6(2.7%) | 0(0.0%) | 75(100%) | 75(100%) |
Note: DASL -(cDNA-mediated Annealing Selection extension and Ligation) microarray
RNA-seq – RNA sequencing
IHC –immunohistochemistry